NCT07192068 - Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

March 13, 2028

Study Completion Date

June 24, 2030

Conditions

Non-Small Cell Lung CancerSarcomaHead &Amp; Neck CancerColorectal CarcinomaEndometrial

Interventions

DRUG

Zanidatamab

"Single arm study where the experimental regimen used for all patients will be zanidatamab, administered intravenously every 3 weeks :~* Patients \<70 kg: 1800 mg IV Q3W on Day 1 of each 21-day cycle~* Patients ≥70 kg: 2400 mg IV Q3W on Day 1 of each 21-day cycle."

Trial Locations (1)

Unknown

Gustave Roussy, Villejuif